Vascular Cures benefits from the expertise of its world-class advisors in healthcare and research to design and implement its high impact programs.
Our Scientific Advisory Board (SAB)
Our Scientific Advisory Board (SAB) includes leading experts in cardiovascular medicine, surgery, pathology, genetics, biochemistry, and clinical trials. The SAB provides guidance on research priorities and innovative collaborative structures. Its members are:
Scott Berceli, MD, PhD
Scott Berceli, MD, PhD is currently Professor of Surgery and Bioengineering at the University of Florida, Chief of Vascular Surgery at the NF/SG VHS. He received his B.S. in Chemical Engineering from the Massachusetts Institute of Technology, followed by his M.D. and Ph.D. in Chemical Engineering from the University of Pittsburgh. He then completed his residency in General Surgery at the Harvard-Beth Israel Deaconess Medical Center and subspecialty training in Vascular Surgery at the University of Washington. Current basic and translational research activities, funded by the NIH, NSF, and the VA, examine the role of physical forces in vascular adaptation following surgical or endovascular intervention. Through development of a multidisciplinary team involving engineers, vascular biologists, mathematicians and clinicians, he has brought a multi-scale, systems level understanding to the dynamics of vascular remodeling, with an emphasis on understanding these events in human pathology.
Michael S. Conte, MD
Michael S. Conte, MD is the Chief Medical Officer of Vascular Cures, Professor and Chief of the Division of Vascular and Endovascular Surgery at UCSF and Co-Director of the UCSF Heart and Vascular Center. Previously, he was the Associate Professor of Surgery at Harvard Medical School and Director of Vascular Surgery Research at Brigham and Women’s Hospital, Boston. He was also Co-Director of the Clinical Trials Group at the Center for Surgery and Public Health, a joint initiative of Harvard Medical School, Brigham and Women’s Hospital, and the Harvard School of Public Health. He has authored or co-authored more than 100 peer-reviewed publications, as well as numerous book chapters and reviews. He is a Distinguished Fellow of the Society for Vascular Surgery and has served on the scientific advisory board of several biotechnology/pharmaceutical companies. He served as an Associate Editor for Circulation, and is currently on the editorial boards of the Journal of Vascular Surgery, Vascular Medicine, Vascular and Endovascular Surgery, and Vascular.
Zorina Galis, Ph.D.
Zorina Galis, Ph.D. is the Chief of Vascular Biology and Hypertension at the National Heart, Lung, and Blood Institute (NHLBI) /National Institutes of Health (NIH), overseeing a large and diverse extramural portfolio of basic, translational, and clinical research. Previously, she rose through the academic ranks at Harvard Medical School, Emory School of Medicine, Georgia Institute of Technology, and Indiana University, and was also the Chief Scientific Officer, Cardiovascular R&D at Eli Lilly and Co. Zorina is recognized for significant scientific contributions to the area of vascular remodeling and for establishing and leading successful interdisciplinary collaborations within and between academia, industry, and the government. She was trained in physics, biophysics, cell biology, pathology, and vascular medicine at the University of Bucharest, Romania, the McGill School of Medicine, Montreal, Canada, and the Harvard School of Medicine, Boston, MA
John Kane, MD, PhD
John Kane, MD, PhD is the Director of the Adult Lipid Clinic at University of California at San Francisco. He earned his medical degree at the University of Oregon School of Medicine, then completed an internship and residency in internal medicine at Stanford University and the University of California, San Francisco (UCSF) and a fellowship in endocrinology at UCSF. His research in lipoprotein metabolism, the management of disorders of lipoproteins, and the genetic bases of heart disease and stroke is known worldwide through his publications in refereed journals and book chapters. Dr. Kane is Professor of Medicine and Professor of Biochemistry and Biophysics, and is an Associate Director of the Cardiovascular Research Institute at UCSF. He is a fellow of the Established Investigator of the American Heart Association. Dr. Kane is a recent recipient of an Outstanding Achievement Award in the Genetics of Lipoprotein Metabolism and Atherosclerosis from the International Atherosclerosis Society. He is a diplomate of the American Board of Clinical Lipidology.
Larry Kraiss, MD
Larry W. Kraiss, MD is Professor and Chief of the Division of Vascular Surgery at the University of Utah. He received his medical degree from Baylor College of Medicine. Dr. Kraiss’ general and vascular surgical training was at the University of Washington in Seattle where he also spent three years in the vascular biology research laboratory of Dr. Alexander Clowes. He joined the faculty at the University of Utah in 1995 where he established an NIH-funded research laboratory studying translational control in endothelial cells and was named Vascular Surgery Division Chief in 2003. He is also Director of the Vascular Surgery Fellowship Program at the University of Utah. Dr Kraiss has twice received teaching awards from the University of Utah general surgery residents. He was the 1997 Wylie Scholar.
Richard Powell, MD
Richard Powell, MD is Section Chief of Vascular Surgery at the Dartmouth-Hitchcock Medical Center in New Hampshire, where he joined the staff in 1997. He received his medical degree from Medical College of Wisconsin, Milwaukee in 1986 and was selected as the 1999 Wylie Scholar. Dr. Powell is currently leading an international clinical trial to evaluate a new type of stent for patients with advanced peripheral artery disease (PAD). He is also working on two clinical trials involving gene and stem cell therapies to prevent limb amputation in patients with advanced peripheral artery disease or critical limb ischemia (CLI).
Aruna Pradhan, MD, MPH
Dr. Pradhan is a cardiologist, epidemiologist and clinical trialist at the Brigham and Women’s Hospital and is actively involved in the design, conduct, and analysis of a number of large-scale observational studies and randomized clinical trials of cardiovascular disease (CVD), peripheral artery disease (PAD), and type 2 diabetes (T2D). As Scientific Director of the Preventive Medicine Cohorts Biorepository, she has technical expertise in collection, long-term storage, quality control and management of biomarker studies. She has served as the Principal Investigator (PI) of the LANCET trial (a randomized clinical trial of insulin glargine for CRP reduction in early T2D) and several NIH R01s including HL103742 evaluating biomarkers of statin-induced diabetes in the JUPITER trial, HL122158 evaluating the effect of low dose methotrexate on PAD incidence within the Cardiovascular Inflammation Reduction Trial (CIRT) and DK088078 evaluating incident diabetes in the Vitamin D and Omega-3 Trial (VITAL). In addition, she is Co-PI of the recently initiated industry-sponsored Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Diabetic Patients (PROMINENT) trial, which will evaluate the selective peroxisome proliferator activator receptor–alpha modulator (SPPARM-) for CVD event reduction in T2D. She actively participates in teaching and mentoring of students and trainees within the Division of Preventive Medicine, and spends one day a week practicing general cardiology and echocardiography at the VA Boston Medical Center.
Paul M. Ridker, MD
Paul M. Ridker, MD is the Eugene Braunwald Professor of Medicine at The Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women’s Hospital in Boston. He also serves on the Board of External Experts for the National Heart Lung and Blood Institute. Dr. Ridker’s research focuses on inflammatory biomarkers and novel strategies for cardiovascular disease detection and prevention.
Dr. Ridker is best known for his work developing the inflammatory hypothesis of heart disease, the clinical application of C-reactive protein (hsCRP) testing to better evaluate cardiovascular risk, and the demonstration in the JUPITER trial that statin therapy is highly effective at reducing heart attack and stroke. He is the author of over 450 original reports, 170 reviews and book chapters, and five textbooks related to cardiovascular medicine. Dr. Ridker is a co-inventor on a series of patents filed by the Brigham and Women’s Hospital and Harvard Medical School that relate to the use of inflammatory biomarkers in cardiovascular disease.
Campbell Rogers, MD
Campbell Rogers, MD serves as the Chief Medical Officer of HeartFlow, Inc. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, Dr. Rogers was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. His research explored biological underpinnings of vascular responses to mechanical injury, and he served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, and is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases. Dr. Rogers was the recipient of research grant awards from the NIH and AHA. He received his A.B. from Harvard College and his M.D. from Harvard Medical School.
Dr. Barry Rubin, MD PhD FRCSC
Dr. Barry Rubin, MD PhD FRCSC is the Chair and Medical Director of the Peter Munk Cardiac Centre (PMCC) at University Health Network, Canada’s largest cardiovascular unit as well as Professor of Surgery at the University of Toronto. He was the 1998 Wylie Scholar. Dr. Rubin has been Chair and CEO of the Mount Sinai Hospital University Health Network Academic Medical Organization since 2003, having been unanimously re-elected to this position three times by his peers. This organization supports teaching, research, innovation, recruitment and retention of 750 physicians at University Health Network and Mount Sinai Hospital. Dr. Rubin’s basic science research laboratory has been continuously funded by the Canadian Institutes of Health Research (CIHR) for 16 years. He has been widely published in high impact journals. He implemented a system throughout PMCC to evaluate and fund innovative research projects. Since 2012, they have funded 37 research projects. According to UNH, Dr. Rubin is one of the world’s most gifted vascular surgeons.
Charles N. Serhan, PhD
Charles N. Serhan, PhD is Director of the Center for Experimental Therapeutics and Reperfusion Injury (CET&RI) at Brigham and Women’s Hospital, and a Professor of Anesthesia at Harvard Medical School, affiliated with the Department of Biological Chemistry and Molecular Pharmacology. Dr. Serhan is working on cellular and molecular mechanisms that are involved in the control of local inflammatory processes, since inflammation plays a role in many organs and diseases. These include cardiovascular diseases, auto-immune diseases, arthritis, and Alzheimer’s disease. The molecules that Dr. Serhan and colleagues are working on can serve as bio-templates for creating designer therapies to stimulate resolution of inflammation and disease.
Edith Tzeng, MD
Edith Tzeng, MD is Professor of Surgery at the University of Pittsburgh and Chief of Vascular Surgery at the VA Medical Center, Pittsburgh. She is focused on the problems of blood vessels healing after injury, bypass, or angioplasty. She received her medical degree from the University of Chicago, The Pritzker School Of Medicine. In 2001 she was awarded Vascular Cures’ Wylie Scholar in Academic Vascular Surgery research grant. Dr. Tzeng is also the Chief of Vascular Surgery at the Veterans’ Administration Medical Center in Pittsburgh, Pennsylvania.
Renu Virmani, MD
Renu Virmani, MD currently serves as President and Medical Director, CVPath, International Registry of Pathology in Gaithersburg, MD. She is recognized as one of the leaders in the search for diagnostic and treatment therapies for vulnerable plaque. Dr. Virmani is also Clinical Professor, Department of Pathology at Georgetown University, University of Maryland-Baltimore, Uniform University of Health Sciences and Vanderbilt University. She is responsible for multiple research grants in the field of pathology – most recently, a $1.3 million grant from the NIH for plaque progression, apoptosis, and inflammation. Dr. Virmani is an active lecturer and has authored over 300 publications in peer-reviewed journals in the field of atherosclerosis and vulnerable plaque, stents, and other cardiovascular diseases. She has received honorary awards that include the Joint Service Commendation Medal for Outstanding Meritorious Service as Chief of Cardiovascular Pathology, Armed Forces Institute of Pathology (1979-1981). Dr. Virmani received her medical degree from Lady Hardinge Medical College, Delhi University, in New Delhi, India.
The Project Voice Advisory Board
The Project Voice Advisory Board is focused on the design and implementation of this innovative program to empower PAD patients, improve patient-physician partnerships and advance adoption of patient-reported outcomes data. It is composed of leading doctors and other stakeholders in vascular health. They provide importance guidance about clinical research studies, patient self-management tools, digital health resources and other topics. Its members are:
Matthew A. Corriere, MD
Matthew A. Corriere, MD, is Chairman of the Advisory Board and an Associate Professor of Surgery at University of Michigan Health System. He was the 2014 Wylie Scholar, for research aimed at increasing participation of patients with peripheral arterial disease (PAD) in their own care by enabling providers to involve them in treatment decisions. In addition to leading the Project Voice Advisory Board, he is the Principal Investigator on Project Voice. Dr. Corriere did his residency at Vanderbilt Medical Center and his fellowship at Wake Forest Baptist Medical Center.
Raul Guzman, MD
Raul Guzman, MD is Associate Professor of Surgery at Harvard Medical Center in Boston. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice for more than 20 years. His primary research focus is on the role of arterial calcification in lower extremity vascular disease, particularly in patients with diabetes and renal failure.
Mary McGrae McDermott, MD
Mary McGrae McDermott, MD is a Professor of Medicine at Northwestern University’s Feinberg School of Medicine. Dr. McDermott is a leading clinical researcher of lower extremity peripheral arterial disease (PAD). Dr. McDermott was the first investigator to demonstrate that asymptomatic leg ischemia is associated with greater lower extremity impairment and increased rates of functional decline, compared to persons without PAD. Her ongoing work includes use of Magnetic Resonance Imaging (MRI) to identify characteristics of atherosclerotic plaque in the superficial femoral artery associated with faster functional decline in persons with PAD.
Ulka Sachdev-Ost, MD
Ulka Sachdev-Ost, is an Associate Professor of Surgery and Chief of Vascular Services at Magee-Women’s Hospital of UPMC. She was the 2008 Wylie Scholar for research to increase understanding of mechanisms that promote blood vessel growth (angiogenesis) and developing new therapies for people suffering from peripheral arterial disease (PAD) and critical limb ischemia (CLI). She received her medical training Mount Sinai School of Medicine. She did her research fellowship at Rockefeller University and her vascular surgery fellowship at Mount Sinai School of Medicine.
Steve Hamburger is an accomplished marketing executive who is currently Chief Marketing Officer at Woo Trading, a provider of predictive analytics models for stock market analysis. Steve also has PAD, Type II diabetes and heart disease, and has forestalled leg bypass surgery for 8 years by maintaining a systematic walking and self-education program. He has an MBA in International Marketing from the University of Oregon.